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1 Abstract 
 
2 Microneedle (MN) technology has emerged as an effective drug delivery system and it has   tremendous 
3 potential as a patient friendly substitute for conventional methods for transdermal drug delivery  (TDD). 
4 In this paper we report on the preparation of lidocaine loaded biodegradable microneedles, which are 
5 manufactured  from  fish  scale  derived  collagen.  Lidocaine,  a common tissue numbing  anaesthetic, is 
6 loaded  in  these  microneedles  with  an  aim  of  delivering  the  drug  with  controlled  skin permeation. 
7 Evaluation of lidocaine permeation in porcine skin has been successfully performed using Franz diffusion 
8 cell (FDC) which has shown that the drug permeation rate increases from 2.5 to 7.5% w/w after 36 hours 
9 and pseudo steady state profile is observed from 5.0 to 10.0% w/w lidocaine loaded microneedle. 
10 Swelling experiments have suggested that  the microneedles have negligible swellability  which    implies 
11 that  the  patch  would  stick  to  the  tissue  when  inserted.  The  experiments  on  MN  dissolution have 
12 depicted that the lidocaine loaded in the patch is lower than the theoretical loading, which is expected 
13 as there can be losses of the drug during initial process manufacture. 
 
14 Keywords:  Fish scale  biopolymer-nanocellulose  microneedle,  dissolution studies,  permeation studies, 
15 swelling studies 
 
16 Introduction 
 
17 Lidocaine is a medication used for numbing tissue in a specific area is most commonly delivered as a 
18 subcutaneous   or   nerve   targeting   injection   rather   than   other   administrative   measures   such as 
19 intravenous   infusion,   nasal   spray,  etc.   The   lipophilic   nature  of  lidocaine   accounts  for  the rapid 
20 redistribution  of  lidocaine  into  peripheral  tissue  after  an  intravenous  (IV)  injection.  Injections with 
21 hypodermic needles used to deliver lidocaine are important from a clinical standpoint but painful.   They 
22 may induce hypersensitivity, bruising, discomfort and bleeding at the site of administration, and in some 
23 cases,  are associated with the risks of contamination (1). Drug-loaded biodegradable microneedle patch 
24 is a unique method of transdermal delivery system. It ensures targeted delivery and the waiting time for 
25 lidocaine  to  act  on  the  nerves  can  be  reduced.  These  are  few  challenges  can  be  overcome       by 
26 microneedle  assisted  transdermal  delivery  of  lidocaine.  Normally  MN  arrays  are  loaded  with     the 
27 concerned drug and applied on skin surface with a certain amount of pressure to be able to pierce the 
28 skin in order to reach beyond the stratum corneum depth. Biodegradable MNs are economical due to 
29 the use of fairly cheap materials, reproducible and are generally safe if MN fragments break off after 
30 piercing  the  skin  (2).  Compared  with  injectable  and  skin-surface  drug  applicants  these  MNs      are 
31 beneficial in terms of constant  needle  lengths being below  the  known depth causing epidermal     pain 
32 stimulation during insertion  (2). Lidocaine  is characterized by  rapid onset  of action and    intermediate 
33 duration  of  efficacy  (3).  It  is  also   the  important  class1-b  antiarrhythmic  drug  and       administered 
34 intravenously for the treatment of ventricular arrhythmias (4). Inhaled lidocaine can be used as cough 
35 suppressor (antitussive) (3). 
 
36 Previous studies have proven that consistent and rigid arrays of    MNs can be fabricated from a blend of 
37 fish scale biopolymer (FSBP) and nanocellulose (NC) (5). These MNs successfully pierce into porcine  skin 
38 and degrade in the skin. These previous study however did not investigate the ability of the FSBP-NC 
39 MNs to load and release drug transdermally. It is important that the MNs are able to penetrate into  the 
40 skin following drug loading and that the loaded drug is released when inserted into the skin. Keeping 
41 this in mind, we aim to investigate the transdermal delivery of lidocaine using biodegradable MNs 
42 fabricated  from  fish  scale  biopolymer-nanocellulose  (FSBP-NC)  composites  using  scales  of     Tilapia 
43 (Oreoschromiss sp) and nanocellulose obtained from bacteria. The lidocaine loaded FSBP-NC MNs are  a 
44 potentially novel state of the art medical device for minimally invasive local anaesthesia. This also has 
45 potential  commercial  implications  in  the  future  when  reproducibility  is  achievable  for  in-vitro drug 
46 delivery of lidocaine. The main objectives of our study are investigating essential pharmaceutics based 
47 properties  such  as  swelling,  lidocaine  permeation  past  the  stratum  corneum  skin  region  and    the 
48 dissolution of the MN array on the skin surface. 
 
49 Method and Materials 
 
50 Materials 
 
51 Fish scales of Tilapia are sourced from the local fish traders in Akoka, Lagos, Nigeria. The scales are  then 
52 transported to the laboratory for further processing. The scales are first washed with tap water to get 
53 rid  of  all  debris.  When  not  used  immediately  the  scales  are  dried  in  open  air  at  an  atmospheric 
54 temperature of about 27 + 3oC and transferred to a plastic jar when completely dried for storage until 
55 when needed. Samples of 12 x 4    arrays of MNs with a mean weight 2.0 g is taken as the representative 
56 for Franz diffusion cell (FDC) and dissolution studies. FDC with an effective diffusional area of 1.77 cm2 
57 and  receptor  volume of 14  ml (Orchid  Scientific Pvt. Ltd, Maharashtra,  India) are  set up  for lidocaine 
58 permeation studies. The dissolution apparatus (DS8000) consists of brown coloured flasks fixed with 
59 paddle impellers set at 25 mm above the flask bottom (Lab India Pvt. Ltd, Maharashtra, India). Polymeric 
60 MNs obtained from MITI systems, Seoul, Korea, are solid tapered in shape with a length of 500   microns 
61 on a substrate 30mm x 15mm in dimension containing 176 MNs in rectangular arrangement. 
 
62 Extraction of fish scale biopolymer 
63 
64 The extraction of biopolymer from fish scales is done according to method presented in our previous 
65 works (5,6) and described here briefly. The required amounts of dried fish scales which have been 
66 washed and cleaned are treated with 0.6% w/v sodium hydroxide to remove non-collagen residues from 
67 the fish scales. The scales are allowed to soak in the sodium hydroxide for 1 hour in a conical flask whilst 
68 swirling  every  15  minutes.  The  scales  are  then  washed  repeatedly  in  water  until  the  wash  water 
69 becomes neutral indicating all sodium hydroxide has been removed. The pre-treated scales are then 
70 transferred  into  the  stainless  steel  vessel,  a  4.5L  pressure  vessel  (PC-70001,  Binatone,  and   Lagos, 
71 Nigeria). Water is then added into the vessel at a ratio of 1 to 3 weights of scales to volume of water. 
72 The vessel is then sealed with pressure of 80 kPa and heated up to 80oC (+5oC) to commence   extraction 
73 of hydrolysed collagen from the scales. After 6 hours the process ends and system is allowed to cool. 
74 This is then followed by filtration to separate the solid from the liquid. The liquid is further centrifuged 
75 to separate smaller solid residues. The supernatant is then transferred to a beaker where it is heated  at 
76 80oC to allow the water to evaporate. Once the liquid becomes viscous, it is transferred onto a flat 
77 rubber base to dry at room temperature for 24hrs. The dried films are separated from the plate and 
78 stored in airtight plastic bags until when needed. 
 
79 Preparation of bacterial cellulose nanofibers (BC) 
 
80 The bacterial cellulose is grown on the surface of a 20 litre glucose solution pre-sterilized and inoculated 
81 with Acetobacter xylinum – ATCC 23767. The solution is composed of 400 g of D-glucose (dextrose,  ACS 
82 reagent, Sigma-Aldrich), 100 g of yeast extract (Fluka, CAS 8013-01-2), 23 g of anhydrous citric acid 
83 (reagent  grade,  Scharlau), 23.8  g  of magnesium  sulphate  (puriss,  p.a.,  Fluka),  145  g of triphosphate 
84 water from Scharlau, and 1 vol% ethanol (96%). The solution is inoculated with a 150 ml fully  developed 
85 pre-inoculated bacteria culture prepared from the preserved strain in the glass ampoule. The time to 
86 generate the uniformly growing cellulose pellicle mats in each pre-inoculated sample is 48h at 28°C. The 
87 wet microbial cellulose pellicle mat formed on the surface of the growth medium is weighed after 48 
88 hours ca. 1.0 kg (including the growth medium inside). The mats are repeatedly boiled in distilled  water 
89 (5×) until all growth medium is removed and is further boiled twice in 10 vol% concentrated NaOH (2 L × 
90 2) for 20 min. The final pH after all removal of residual chemicals is neutral (pH ≈ 7). 
 
91 The bacterial cellulose (BC) nanofibers composed of the unique fibrils are extracted from the 1.0 kg of 
92 bacterial  cellulose  is  obtained  by  shredding  the  mat  using  a  blender  followed  by  compressing the 
93 suspension in a SEFAR  polyamide mesh (PA 1000 120/305-35W with 46 μm    openings)  to  remove  the 
94 water. The total mass of wet cellulose is 148 grams. The water remaining in the compressed cellulose  is 
95 87.2 ± 0.8%, corresponding to the dry bacterial cellulose content of 18.9 g. The 148 g of cellulose is 
96 added to a 2L aqueous hydro sulphuric acid solution containing 30 vol% of reagent grade acid (Merck 
97 KGaA), and is stirred at 60 ± 0.5 °C (300 rpm). The suspension is stirred for 7 hours isothermally. The 
98 extraction is terminated by the addition of 2 L cold MilliQ water and isothermally centrifuged at 10000 
99 rpm (15 °C) for 10 min, four times. The total amount of extracted CNFs is 10.4 g (55 wt% yield), from 148 
100 g of shredded cellulose (or 18.9 g of corresponding dry bacterial cellulose). The specific surface area of 
101 the CNFs is calculated to ca. 160 m2  g−1  from size distributions of a minimum of 500 counted fibrils 
102 deposited on TEM grids. Before using in the composites, the BC is prepared as a 28 mg/ml aqueous 
103 suspension. 
 
104 Production of lidocaine loaded fish scale biopolymer – nanocellulose films (FSBP-NC) 
 
105 For this study a 15% w/w concentration of NC per polymer weight is used based on previous findings 
106 that a higher concentration of NC gave improved mechanical properties and since the key goal of this 
107 study is to study the effect of drug loading, the concentration of NC is kept constant. The method  which 
108 is used to prepare the films is similar to that reported in our previous publication (5) and briefly outlined 
109 here. FSBP is weighed and dissolved in distilled water at 45oC until all the solid is completely dispersed in 
110 water, lidocaine powder is then added at the desired concentration for each formulation, ranging   from 
111 0, 2.5, 5, 7.5 to 10% w/w. This is placed under continuous stirring on a magnetic stirrer as the required 
112 amount of NC is added drop wise. The mixture is then stirred for 1 hour at 200 rpm at 45oC followed   by 
113 increasing  the  temperature  to   80oC  until  all  water  gets  evaporated.  This  viscose  blend  is       then 
114 transferred onto a silicone plate and allowed to dry at room temperature for 24 hours after which it is 
115 placed in airtight plastic bags until needed. 
 
116 MN Fabrication 
 
117 MNs are produced according to method reported in Olatunji and Olsson (5). Silicone elastomer with 
118 activator and base mixed in the ratio 1:10 (Bristol Scientific, Lagos, Nigeria) is poured over solid MN 
119 moulds and left to cure for 48 hrs at room temperature. The solid mould is then separated from the 
120 silicone mould haven formed templates for producing MNs. Films of FSBP-NC-Lidocaine are then cut out 
121 in 2cm by 2cm squares and placed on the mould. This is then placed in between two metal sheets and 
122 pressed with approximately 10 N of force while heating at 80oC for 5 minutes. The power is then 
123 switched  off  and  the  mould  transferred  to  cooling  blocks  to  cool  after  which  the  formed  MN    is 
124 separated from the mould Fig. 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
125 
126 Fig. 1 Schematic diagram of MN fabrication 
 
127 Swelling studies of fish scale collagen MNs 
 
128 As these fish biopolymer MNs are biodegradable in nature, swelling studies are performed in order to 
129 determine the weight gain due to absorption of moisture from the skin section on application. This is 
130 done by measuring the difference in weight of the MN patch. The dry weight of the MN patch is first 
131 noted down and then weighed again after its application on the skin. Due to the absorption of  moisture 
132 from the skin the MN patch shows increase in weight. The increase is however limited to a particular 
133 time of application, after which weight decreases with increased time of application due to loss of 
134 polymeric mass  into  the porcine  skin. Patch size of approximately 1.5cm2  is  used.  Thumb pressure    is 
135 used to apply the patch onto the skin section. The porcine skin section is treated to achieve physiological 
136 temperature of 37˚C. The time of application is variable for each patch. In vitro studies on lidocaine   fish 
137 scale  MNs  suggests  absorption  of  moisture  (gain  weight)  and  degradation  (loss)  on  application  to 
138 porcine skin, thus helping in drug permeation. 
 
139 Franz diffusion cell permeation of lidocaine from fish collagen MNs 
 
140 In vitro studies using porcine skin are performed in triplicate using FDCs as outlined in the Materials 
141 which are connected in series are equilibrated to physiological conditions (37.4 ± 0.5°C).   The    MNs are 
142 applied to skin by a firm thumb pressure directed at the middle of the patch. A drug free, sticky tape is 
143 carefully placed over the MN base in order to hold the patch as stationary as possible. The timer is 
144 immediately started and receptor volumes (0.5 ml) are removed and subsequently replaced with fresh 
145 saline. Each receptor volume is analysed by HPLC. 
146 Dissolution of lidocaine from fish scale collagen MNs 
 
147 A dissolution apparatus as described in the Materials section is set up containing saline solution (0.9 % 
148 w/w)  maintained  at  32℃. Each  2.5 %  to 7.5 %  w/w  lidocaine  loaded MN  patch  are  pressed  on the 
149 parafilm for 5-10 sec with thumb pressure and then covered in parafilm exposing only the MNs to the 
150 saline solution inside the flask. The covered substrate is bound to a small coin as a “sinker” to weigh  the 
151 MN patch to the bottom of the flask. The 10 % w/w lidocaine loaded MN patch is devoid of any parafilm 
152 and thus fixed to a mesh. The parafilm wrap prevents contact of saline solution with the substrate of 
153 MN patches. At predetermined periodic intervals, a known volume of saline solution is removed in order 
154 to quantify the lidocaine dissolution cumulatively. 
 
155 Skin insertion studies using cryotome 
 
156 In order to confirm if MNs can successfully pierce through the stratum corneum, skin insertion studies 
157 have been carried out using method describe by Cheung et al (7). Briefly, the skin samples are treated 
158 with MNs followed by application of a 50:50 v/v solution of methylene blue. The stained samples are 
159 then  placed  in  the  cryotome  machine  for  24  hours  after  which  histological  sections  are  cut    and 
160 visualized using the microscope. 
 
161 Results 
 
162 Microstructural nanocomposite characteristics: 
 
163 The blends of FSBP/NC are observed using transmission and scanning electron microscopy   (TEM/SEM). 
164 The TEM and SEM images obtained are shown in Fig. 2a while 2b, respectively. Fig. 2a shows the 
165 micrographs  of  the  obtained  fibres  before  preparing  composites.  Fig.  2b  shows  the cross-sectional 
166 scanning electron microscope (SEM) images obtained by using a Hitachi FE-SEM S-4800 microscope after 
167 sputtering the composites 20 seconds by a platinum/palladium coating (applied in a Cressington  208HR 
168 sputter). The nanocellulose (NC) suspension used shows good dispersion of the nanocellulose fibres in 
169 water  as  the  individual  cellulose  fibres  are  evenly  dispersed  in  the  suspension.  Fig.  2b  shows  the 
170 dispersion of the (NC) fibres within the FSBP matrix. The bacteria cellulose in this case shows very high 
171 compatibility with the fish scale biopolymer. The NC fibres retained their individual length and diameter 
172 and in most of the formulation the NC exists as individual fibres rather than clustered. 
 
173 Fabrication of MNs: 
 
174 MNs containing varying concentration of lidocaine (0, 2.5, 5, 7.5, 10 w/w %) are successfully  fabricated. 
175 For this particular study, both the MNs and the base substrate contain lidocaine. The MNs form sharp 
176 tips which replicate the structure of the master moulds used. The MNs formed from the master  moulds 
177 are cut into approximately equal sizes by length and width. Each array contained 48    MNs arranged in a 
178 12 by 4 pattern as shown in Fig. 3. 
 
179  
 
180 Fig. 2a. TEM showing cellulose microfibrils before preparing a composite. 
 
181  
 
182 Fig. 2b. HR-SEM showing FSBP-NC composite at 350x, 12000x, 15000x and 70000x resolutions 
183  
 
184 Fig.  3.  Fish  scale  biopolymer/nanocellulose  MN  array  containing  Lidocaine  insertion  studies    using 
185 cryotome 
 
186 Fig. 4 shows the cavity created by a MN piercing on a porcine transverse skin section made by cryotome. 
187 The blue staining on the image indicates the methylene blue stained stratum corneum. From the  image 
188 the outline of the region pierce by the MN can be seen (marked by red circle). Thus indicating that the 
189 MNs are able to pierce through the stratum corneum layer and reach the lower layer of the epidermis. 
 
190  
 
191 Fig. 4a. Cryotome image of skin section showing MN piercing. 
 
192 Permeation studies 
193 The lidocaine permeation profiles show an increasing trend with time for all four loading concentrations 
194 (2.5-10 % w/w) (Fig 5). The error bars (SEM) indicate good reproducibility of pooled data up to 36  hours 
195 for all loading concentrations (Fig. 5). A one-tailed F-test was performed to compare the significance   of 
196 variation between data points representing flux at t = 42 hours (Fig. 54). The chosen independent time 
197 point is the representative of the slope gradient representing the permeation flux against lidocaine 
198 loading (Fig. 65). The F2, 2  = 19.00 is the accepted critical value (P=0.05). The calculated F-test values 
199 varied from 3.60 to 1.14 with comparing 2.5 % till 10 % of lidocaine loading. As F-test values were less 
200 than the accepted critical value, the null hypothesis is retained and the variation between lidocaine 
201 permeation  representatives  of  flux  is  insignificant.  Nevertheless  from  first  inspection there is visible 
202 separation of data points at t=42 hours and a slight significance in variation (Fig. 54). Appearance of a 
203 rate limiting step is observed within an 18 hour period for lidocaine 2.5, 5 and 10 % w/w loading (Fig. 5). 
204 This distinct rate limiting observation indicates that most of the drug is in the process of diffusing slowly 
205 through the skin so the lidocaine permeated amount is less in the receptor of FDC. The lidocaine 7.5 % 
206 w/w MN shows faster permeation within 30 hrs compared to the others, especially 10 % w/w. 
 
207 Pseudo steady state profile is observed for 5.0 - 10.0 % w/w lidocaine MN loading after 30 hours (Fig. 6). 
208 The apparent flux shows increasing trends for 2.5 - 7.5 % w/w after 36 hours. 
 
209  
 
210 Fig. 5. The permeation of lidocaine through full thickness skin from loaded MNs (Error bars represent 
211 the standard error of mean SEM). 
212  
 
213 Fig. 6. The permeation fluxes of lidocaine after a period of 36 hours through full thickness skin from 
214 loaded MNs (Error bars represent SEM). 
 
215 Swelling studies 
 
216 The swelling studies are performed to analyse the swellability of these collagen MNs, which will give a 
217 fair interpretation of how well they absorb moisture from the tissue and reach the maximum swelling 
218 point in order to deliver drug into the system. We took MN insertion time as one of the variable   factors 
219 into consideration (keeping other factors like pressure applied and size of the MN patch constant)  while 
220 observing swelling properties. 
 
221 From the experiments we have found that the MN patches have taken around 50 to 55 seconds to reach 
222 the maximum swelling point. Maximum mean % change in mass is 1.12% (Fig. 7). After which they show 
223 degradation and thus loss of mass. It is also observed that the extent of swelling is not very high which 
224 ensured the patch to stick to the tissue surface and hence preventing it from falling out. 
225  
 
226 Fig. 7. Change in mass of lidocaine MN patches (Error bars represent SD). 
 
227 Dissolution studies 
 
228 In order to determine the experimental lidocaine loading in MNs from theoretical loading (2.5 - 10.0% 
229 w/w),  dissolution  studies  allow  the  complete  dissolution  of  drug  molecules  in  excess  solvent.  The 
230 dissolution profile outlines rapid lidocaine release for 7.5% and 10 % w/w loading (Fig. 8). The highest 
231 plateau values on the hyperbolic shaped curve represent the cumulative amount of lidocaine release   in 
232 dissolution media. The 10 % w/w lidocaine loaded MN underwent full dissolution including the substrate 
233 so therefore very high fold values are reported here. The theoretical loading mass ranges of lidocaine 
234 are from 5 to 22 mg for 2.5 to 10.0 % w/w in 2g (nanocellulose 15% of FSBP) of total material content 
235 required  to  make  1  batch  of  480  MNs.  From  the  plateau  obtained  from  dissolution  profiles,   the 
236 experimental loading mass of lidocaine in the MNs is 0.3 mg for 2.5 and 5.0 % w/w theoretical loading 
237 (Fig. 8). The experimental loading mass for 7.5 % w/w MN is 1.6 mg and for the whole MN including 
238 substrate is 7.8 mg for 10 % w/w MN (Fig. 8). The percentage loading of lidocaine is calculated per MN 
239 batch of 480 MNs. Therefore the practical percentage loading is 0.3%, 0.3%, 1.5% and 7.5% lidocaine 
240 from 2.5 to 10 % w/w theoretical loading of MNs.       The lidocaine loading is low for the needle body as 
241 examined for  2.5  to  7.5  %  w/w  theoretical loading. Lidocaine  is not  a  very low  potent  and     highly 
242 expensive  drug  so  low  percentage  loading  could  be  permissible  in  further  developmental   studies. 
243 Nevertheless a target of up to 35% lidocaine loading is ideal for the needle body itself.  At micron  scales 
244 it  is  expected  that  losses  of  drugs  during  processing  is  high  unless  new  processing  solutions     by 
245 preventing lidocaine building up into the substrate is looked into. 
 
246  
 
247 Fig. 8. Dissolution studies of 2.5%, 5%, 7.5%, 10% lidocaine loaded MNs. 
 
248 Discussion 
 
249 The ability of biopolymer extracted from fish scale to form uniform blend with cellulose particles can  be 
250 attributed  to  the  protein-polysaccharide  intermolecular  bonding  due  to  the  presence  of  the amide 
251 linkage in protein of the fish scale which is essentially hydrolysed collagen and the OH group of the 
252 cellulose polysaccharide. These forces allow good compatibility ion protein    polysaccharide composites 
253 (8).   Both  DSC  and FTIR  studies  are  not  conducted because  the  aim of  this  study  was  the lidocaine 
254 release from microneedle polymeric composite. This shall be performed in a further study. 
 
255 The  flexibility  of  the  gelatine  combined  with  the  structural  strength  of  the  cellulose  resulted  in a 
256 composite  material  with  sufficient  flexibility  for  micromoulding  and  a  resulting  MN  structure  with 
257 sufficiently sharp and rigid tips. From the results of the skin insertion studies using cryotome it can be 
258 seen that the MNs successfully pierced the stratum corneum layer. This is an essential requirement   for 
259 MNs as they must be able to pierce the stratum corneum in their dry state such that they maintain their 
260 structural integrity in the process of piercing the stratum corneum layer. Other studies in literature have 
261 also used similar techniques with porcine skin to determine the ability of MNs to pierce the skin (7,9). 
262 The reproducibility of the fabrication process is also important as it allows formation of  microstructures 
263 with consistent dimensions. 
 
264 During the drug loading step of lidocaine in collagen we have assumed a well-mixed system as the   drug 
265 is dissolved in vehicle itself. Lidocaine is relatively inexpensive and quite potent so the drug is allowed to 
266 appear in the base substrate of the MN body. Despite allowing lidocaine to accumulate in the base 
267 substrate, there is no contradictory trend in lidocaine flux from 2.5% w/w to 7.5 % w/w loading. The 
268 tertiary amide groups of lidocaine seem less ionically attracting the collagen amino groups for binding. 
269 Fundamentally this physicochemical property for binding lidocaine to fish collagen is less likely to be 
270 stronger at 7.5 % w/w as compared with others, and therefore faster initial release of lidocaine in skin 
271 plasma.  This  result  provide  significant  evidence  that  lidocaine  loaded  MNs  made  from       FSBP-NC 
272 composite can act as delivery systems to administer lidocaine transdermally. 
 
273 In this particular study the MNs did not demonstrate large swelling capability compared to the  hydrogel 
274 MNs reported in literature (9). As the results from the permeation studies show, despite not showing 
275 significant swelling the MNs are able to release loaded drugs into the skin. Rather than the mechanism 
276 of absorbing water and swelling, due to the adhesive nature of the gelatine, the MNs in this case   insert 
277 into the skin and absorb moisture which allows the drug polymer matrix to dissociate thereby   releasing 
278 the   drug   from   the   polymer  materials.  The   MN  material   in   this  case   comprises  of  protein and 
279 polysaccharide   material   which   are   both   biocompatible   naturally   occurring   polymer   such    that 
280 dissociation into the skin pose no health hazard. 
 
281 The dissolution studies show that the lidocaine loaded into the MNs is released in distilled water   within 
282 an hour which indicates that the lidocaine loaded FSBP-NC MN can act as medium to fast release MNs. 
283 The  release  did not  occur in seconds  therefore  they  do  not  apply  as  rapid release  polymeric   MNs. 
284 Further studies will explore the dose dependent release rate in more details. 
 
285 Conclusion 
 
286 The  findings  of  this  study  provide  evidence  that  MN  arrays  produced  from  fish  scale  biopolymer- 
287 nanocellulose blends loaded with lidocaine can pierce the stratum corneum and dissolve in the skin to 
288 release the loaded drug. In particular the MNs with loaded lidocaine 7.5 % w/w outline a favourable 
289 permeation of the drug through skin. Also, the drug loading is considerably higher as dissolution  studies 
290 have shown a higher release for patches loaded with 5.0 % lidocaine than those loaded with 2.5 %   w/w 
291 lidocaine.   Logically the greater the drug loading, the greater the drug release as long as the drug 
292 carrying vehicle is not saturated. Further studies will need to explore optimizing drug release rate by 
293 varying the formulation of the biopolymer material. 
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